NewAmsterdam Pharma (NAMS) Competitors $18.51 -0.84 (-4.34%) Closing price 04:00 PM EasternExtended Trading$18.50 -0.01 (-0.03%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS vs. ROIV, RVMD, ELAN, BPMC, BBIO, VRNA, TLX, TGTX, GRFS, and LNTHShould you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma (VRNA), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Grifols (GRFS), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. NewAmsterdam Pharma vs. Roivant Sciences Revolution Medicines Elanco Animal Health Blueprint Medicines BridgeBio Pharma Verona Pharma Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Grifols Lantheus NewAmsterdam Pharma (NASDAQ:NAMS) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation. Which has more volatility & risk, NAMS or ROIV? NewAmsterdam Pharma has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Do analysts rate NAMS or ROIV? NewAmsterdam Pharma presently has a consensus price target of $43.00, suggesting a potential upside of 133.77%. Roivant Sciences has a consensus price target of $17.50, suggesting a potential upside of 60.62%. Given NewAmsterdam Pharma's higher probable upside, equities analysts clearly believe NewAmsterdam Pharma is more favorable than Roivant Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Roivant Sciences 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of NAMS or ROIV? 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 7.9% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to NAMS or ROIV? In the previous week, Roivant Sciences had 10 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 15 mentions for Roivant Sciences and 5 mentions for NewAmsterdam Pharma. Roivant Sciences' average media sentiment score of 1.44 beat NewAmsterdam Pharma's score of 1.34 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Roivant Sciences 12 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, NAMS or ROIV? Roivant Sciences has higher revenue and earnings than NewAmsterdam Pharma. Roivant Sciences is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNewAmsterdam Pharma$47.14M42.85-$176.94M-$1.88-9.78Roivant Sciences$122.59M63.42$4.35B-$0.15-72.63 Is NAMS or ROIV more profitable? NewAmsterdam Pharma has a net margin of 0.00% compared to Roivant Sciences' net margin of -119.54%. NewAmsterdam Pharma's return on equity of 0.00% beat Roivant Sciences' return on equity.Company Net Margins Return on Equity Return on Assets NewAmsterdam PharmaN/A N/A N/A Roivant Sciences -119.54%-14.05%-12.81% Does the MarketBeat Community prefer NAMS or ROIV? Roivant Sciences received 27 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.55% of users gave NewAmsterdam Pharma an outperform vote while only 78.57% of users gave Roivant Sciences an outperform vote. CompanyUnderperformOutperformNewAmsterdam PharmaOutperform Votes2896.55% Underperform Votes13.45%Roivant SciencesOutperform Votes5578.57% Underperform Votes1521.43% SummaryNewAmsterdam Pharma and Roivant Sciences tied by winning 9 of the 18 factors compared between the two stocks. Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NAMS vs. The Competition Export to ExcelMetricNewAmsterdam PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.02B$6.51B$5.38B$8.42BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-9.778.9726.6219.77Price / Sales42.85253.27392.02116.56Price / CashN/A65.8538.2534.62Price / Book5.266.486.814.53Net Income-$176.94M$143.98M$3.23B$248.18M7 Day Performance-1.90%3.37%4.05%1.06%1 Month Performance13.12%7.83%11.64%14.68%1 Year Performance-5.57%-2.24%17.11%6.87% NewAmsterdam Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NAMSNewAmsterdam Pharma2.5235 of 5 stars$18.51-4.3%$43.00+132.3%-2.5%$2.03B$47.14M-9.854Gap UpROIVRoivant Sciences1.9915 of 5 stars$10.84+0.5%$17.50+61.4%-2.9%$7.73B$122.59M-72.26860Positive NewsRVMDRevolution Medicines4.4108 of 5 stars$39.93+1.0%$67.08+68.0%+1.1%$7.44B$742,000.00-11.12250Positive NewsELANElanco Animal Health3.5226 of 5 stars$13.24+2.5%$15.17+14.6%-23.1%$6.58B$4.43B33.109,800Analyst ForecastGap UpBPMCBlueprint Medicines2.6687 of 5 stars$101.21-0.5%$126.56+25.0%-1.2%$6.54B$562.12M-93.71640Positive NewsBBIOBridgeBio Pharma4.6002 of 5 stars$33.69-0.4%$57.09+69.5%+14.2%$6.40B$127.42M-11.82400Positive NewsInsider TradeVRNAVerona Pharma2.6775 of 5 stars$72.58+1.8%$81.50+12.3%+484.7%$5.88B$118.54M-37.8030Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.54-0.8%$22.00+33.0%N/A$5.59B$783.21M0.00N/AGap DownTGTXTG Therapeutics3.8254 of 5 stars$34.98+1.8%$40.80+16.6%+115.2%$5.55B$386.39M-349.77290Positive NewsGRFSGrifols3.2195 of 5 stars$8.00+3.1%N/A+4.7%$5.50B$7.21B6.8426,300Positive NewsLNTHLantheus4.458 of 5 stars$78.25-3.7%$132.67+69.5%-7.3%$5.41B$1.54B13.02700Positive News Related Companies and Tools Related Companies Roivant Sciences Alternatives Revolution Medicines Alternatives Elanco Animal Health Alternatives Blueprint Medicines Alternatives BridgeBio Pharma Alternatives Verona Pharma Alternatives Telix Pharmaceuticals Limited American Depositary Shares Alternatives TG Therapeutics Alternatives Grifols Alternatives Lantheus Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NAMS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
